Solti Group — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

3 Recruiting

10 Completed trials

4 Countries active

17 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 2 Phase II: 9 Phase I (Other): 2

100%

10 of 10 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

PERTUZUMAB 2 RIBOCICLIB 2 TISLELIZUMAB 2 TRASTUZUMAB DERUXTECAN 2 ATEZOLIZUMAB 1 ELACESTRANT DIHYDROCHLORIDE 1 IPATASERTIB 1 LETROZOLE 1 OLAPARIB 1 PALBOCICLIB 1 PATRITUMAB DERUXTECAN 1 PEMBROLIZUMAB 1

All trials

13 total

Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting

2025-521805-41-00 Phase III 3 countries PERTUZUMAB; TRASTUZUMAB DERUXTECAN
Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan. Recruiting

2023-505385-28-00 Phase II 1 country SACITUZUMAB GOVITECAN
Phase II, multicenter, randomized, open-label study of premenopausal women with luminal breast cancer investigating the effect of elacestran… Recruiting

2023-503373-37-01 Phase II 1 country ELACESTRANT DIHYDROCHLORIDE
Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Phase II 2 countries LETROZOLE; RIBOCICLIB
Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial Ended

2023-503403-28-00 Phase II 1 country PATRITUMAB DERUXTECAN
Pre- and post-menopausal women or men with advanced (loco-regionally recurrent not amenable to curative therapy or metastatic) HER2-positive… Ended

2023-508829-28-00 Phase II 1 country ATEZOLIZUMAB
Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201 Ended

2023-508830-33-00 Phase II 1 country TRASTUZUMAB DERUXTECAN
Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended

2023-508828-35-01 Phase III 2 countries PALBOCICLIB; RIBOCICLIB; TISLELIZUMAB
Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negat… Ended

2024-511875-14-00 Phase II 1 country OLAPARIB
Efficacy of antibodies targeting PD1 protein in patients with advanced or metastatic tumors that express high levels of PD1 biomarker. Ended

2023-508549-41-00 Phase II 1 country SPARTALIZUMAB; TISLELIZUMAB
Clinical Trial to evaluate the efficacy of immunotherapy in a subset of Hormonal Receptor-positive/HER2-negative advanced breast cancer pati… Ended

2023-508546-17-00 Phase II 1 country PEMBROLIZUMAB
Inhibition of AKT in combination with antibodies targeting the protein HER2 in patients with advanced or metastatic breast cancer and with a… Ended

2023-508826-92-00 Phase I (Other) 1 country IPATASERTIB; PERTUZUMAB; TRASTUZUMAB
Combination of Talimogene Laherparepvec (modified Herpes Virus) with atezolizumab (monoclonal antibody) in patients with residual breast can… Ended

2023-508550-25-00 Phase I (Other) 1 country

Showing 1–13 of 13 trials

← All sponsors A–Z